GTCbio is proud to present the 5th Novel Protein Therapeutics Conference to be held on June 25-26, 2018 in Boston, MA. This conference strives to connect industry and academic researchers in the protein therapeutics field to facilitate discussion on the current state of the industry and discuss recent studies and challenges involved in therapeutic development.
Representatives from big pharma, academic institutions and government research labs will present data and case studies on key topics including antibody drug conjugates, bispecific antibodies, antibody combinations, and check point inhibiting antibodies. Attend to learn and network with key opinion leaders in a highly interactive and intimate environment!
- Antibody and Protein Discovery Technologies
- Emerging Antigens, Neoantigens and Novel Therapeutic Targets
- Targeting Disease with Non-Antibody Scaffolds & Polyclonal Antibodies
- Advances in Antibody Engineering
- Regulatory Considerations of Bringing Antibody Therapies to Market
We hope to see you there!
The 2018 Advisory Committee
|2017 Program Director|
|Victor-Jeffrey Leyton, Université de Sherbrooke|
|2017 Advisory Board Members|
|Neeraj Agrawal, Amgen|
|Ahuva Nissim, Queen Mary University|
|Amandeep Gakhal, Sutro Biopharma|
|Ann White, University of Southampton|
|Bill Harriman , Crystal Bioscience|
|Birgit Schoeberl, Merrimack Pharmaceuticals|
|Elad Firnberg, Revolve Biotechnologies|
|Ernesto Freire, Johns Hopkins University|
|Nicolas Fischer, Novimmune SA|
|Gregory Adams, Eleven Biotherapeutics|
|Janos Luka, Walter Reed Army Institute of Research|
|Matthew Robinson, Immunome, Inc|
|Michael R. Dyson, IONTAS Ltd|
|Andreas Pahl, Heidelberg Pharma|
|Pedro Berraondo López, CIMA, University of Navarra|
|Darren Schofield, MedImmune|
|Seema Kumar, EMD Serono|
|Jamshid Tanha, University of Ottawa|
|Thomas Pillow, Genentech|
|Medha J. Tomlinson, Abbvie|
|Yan Chen, Genentech|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Wyatt Technology is the recognized leader in instrumentation for determining the absolute molar mass, size, charge and interactions of macromolecules and nanoparticles in solution. These tools include: in-line multi-angle static light scattering, high-throughput dynamic light scattering, differential refractometry, electrophoretic mobility, differential viscosity, field flow fractionation and automated composition gradient.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.